SCHEMBL1896933

SCHEMBL1896933

CC(C)NC(=O)CC#N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8015155 0.84
SCHEMBL11523812 0.82 MCL1 (0.52)
SCHEMBL6317395 0.82 MCL1 (0.52)
SCHEMBL29232958 0.80 MCL1 (0.50)
SCHEMBL6317467 0.80 MCL1 (0.52)
SCHEMBL30628698 0.80 MCL1 (0.50)
SCHEMBL10428284 0.79 MCL1 (0.48)
SCHEMBL6315460 0.79 MCL1 (0.48)
SCHEMBL12724752 0.78
SCHEMBL6321739 0.77 MCL1 (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118946553-A SARM1 inhibitor compound, pharmaceutical composition comprising the same, and preparation method and use thereof 深圳众格生物科技有限公司 2024-11-12 CN disclosed
US-RE50030-E1 Methods to treat lymphoplasmacytic lymphoma DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-07-02 US disclosed
US-12024531-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2024-07-02 US disclosed
WO-2024081311-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2024-04-18 WO disclosed
CN-111491939-B Immunoproteasome inhibitors 普林斯匹亚生物制药公司 2023-12-26 CN disclosed
WO-2023193809-A1 SARM1 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USES THEREOF 深圳众格生物科技有限公司 2023-10-12 WO disclosed
US-20230212164-A1 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-07-06 US disclosed
US-20230133165-A1 IMMUNOPROTEASOME INHIBITORS PRINCIPIA BIOPHARMA INC. 2023-05-04 US disclosed
EP-3710457-B1 IMMUNOPROTEASOME INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2022-08-03 EP disclosed
CN-113801187-A Preparation and application of Michael acceptor type main protease inhibitor targeting novel coronavirus 南开大学 2021-12-17 CN disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed
WO-2002070483-A1 HETEROCYCLIC DIAMIDE INVERTEBRATE PEST CONTROL AGENTS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2002-09-12 WO disclosed
EP-0683159-A1 Substituted furoxanes HOECHST AKTIENGESELLSCHAFT (DE) 1995-11-22 EP disclosed
US-5446194-A Pharmacologically active catechol derivatives ORION-YHTYMA OY (FI) 1995-08-29 US disclosed
US-5283352-A Transferase inhibitor ORION-YHTYMA OY (FI) 1994-02-01 US disclosed
US-5112861-A Inhibitors of catechol-methyl-transferase enzyme, levodopa ORION-YHTYMA OY (FI) 1992-05-12 US disclosed
US-4963590-A ENZYME INHIBITOR FOR TREATING PARKINSON'S DISEASE ALONG WITH DOPA;POTENTIATION ORION-YHTYMA OY (FI) 1990-10-16 US disclosed
EP-0010165-B1 PROCESS FOR THE PREPARATION OF 6-HYDROXYPYRID-2-ONES CASSELLA Aktiengesellschaft (DE) 1982-01-20 EP disclosed
US-4284782-A Process for the manufacture of 6-hydroxypyrid-2-ones CASSELLA AKTIENGESELLSCHAFT (DE) 1981-08-18 US disclosed
EP-0010165-A1 Process for the preparation of 6-hydroxypyrid-2-ones CASSELLA Aktiengesellschaft (DE) 1980-04-30 EP disclosed